C
21.47
0.21 (0.99%)
| 前收盘价格 | 21.26 |
| 收盘价格 | 21.14 |
| 成交量 | 155,750 |
| 平均成交量 (3个月) | 406,577 |
| 市值 | 619,299,968 |
| 市盈率 (P/E TTM) | 34.63 |
| 价格/销量 (P/S) | 1.60 |
| 股市价格/股市净资产 (P/B) | 1.23 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 |
| 营业毛利率 | -1.46% |
| 营业利益率 (TTM) | -31.74% |
| 稀释每股收益 (EPS TTM) | -0.190 |
| 季度收入增长率 (YOY) | 20.60% |
| 总债务/股东权益 (D/E MRQ) | 5.87% |
| 流动比率 (MRQ) | 9.37 |
| 营业现金流 (OCF TTM) | 65.67 M |
| 杠杆自由现金流 (LFCF TTM) | 44.64 M |
| 资产报酬率 (ROA TTM) | -1.80% |
| 股东权益报酬率 (ROE TTM) | -1.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | Castle Biosciences, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 2.98% |
| 机构持股比例 | 93.01% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (Scotiabank, 86.31%) | 购买 |
| 中 | 37.00 (72.33%) | |
| 低 | 35.00 (Lake Street, 63.02%) | 购买 |
| 平均值 | 37.33 (73.87%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 16.42 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Scotiabank | 21 May 2025 | 40.00 (86.31%) | 购买 | 16.02 |
| Canaccord Genuity | 06 May 2025 | 37.00 (72.33%) | 购买 | 16.62 |
| Lake Street | 06 May 2025 | 35.00 (63.02%) | 购买 | 16.62 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合